Pfizer Partnership Propels Small-Cap Biotech Sangamo To Second-Most Active Stock On Stocktwits

Sangamo Therapeutics Inc. (SGMO) shares climbed over 6% to $0.745, with the biotech firm experiencing the second-highest spike in weekly retail message volumes behind Wall Street favorite Nvidia Corp.

HC Wainwright & Co. reaffirmed its Buy rating on Sangamo, maintaining a $5 price target. The analyst note comes a week after the company, in partnership with Pfizer Inc. (PFE), reported promising results from a Phase 3 study of an investigational hemophilia A gene therapy for adults.

The study not only met its primary objective but also showed superiority in key secondary endpoints compared to prophylaxis.

Despite this positive news, Sangamo’s stock remains under $1 per share. A Seeking Alpha analysis highlighted Sangamo’s precarious financial position, noting that the company is nearly out of cash and potentially facing bankruptcy.

As of March 31, Sangamo had approximately $54.40 million in cash and cash equivalents, enough to fund operations only into the third quarter, according to the report.

Retail investors on Stocktwits show a bullish sentiment towards SGMO (57/100), with many optimistic that the Pfizer collaboration will significantly boost the stock.

Sangamo is eligible to earn up to $220 million in milestone payments from Pfizer upon achieving certain regulatory and commercial milestones for the drug candidate, giroctocogene fitelparvovec. If approved and commercialized, Sangamo would also be eligible to receive product sales royalties ranging from 14% to 20%.

Currently, Sangamo’s market capitalization stands at $145.26 million, and the stock has risen over 42% year-to-date.

As retail interest surges, Sangamo’s partnership with Pfizer and the promising Phase 3 results offer a beacon of hope for investors betting on the biotech’s potential turnaround.

Photo courtesy: Sangamo